Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Mereo BioPharma
With
Syneos Health
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with a confirmed diagnosis of alpha-1-anti-trypsin deficiency and a PiZZ, null or other rare geno/phenotype and serum anti-alpha1 antitrypsin levels of less than 11uM
FEV1 ≥20% predicted
Computerised tomography (CT) scan evidence of emphysema
Non-smokers
You may not be if
Primary diagnosis of bronchiectasis
An ongoing acute exacerbation of the underlying lung disease
Underlying liver disease or abnormal liver function tests
Previous augmentation therapy within 6 months of dosing
Clareo Health | A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.
